HR-2569-116
ASSUMING FIRST SPONSORSHIP - Mrs. Carolyn B. Maloney (NY) asked unanimous consent that she hereafter be considered as the first sponsor of H.R. 2569, a bill originally introduced by Representative Cummings, for the purpose of adding cosponsors and requesting reprintings pursuant to clause 7 of rule XII. Agreed to without objection.
What it does
This bill would establish federal grant programs to fund treatment, recovery, and harm reduction services for people with substance use disorders and opioid addiction. It would also create a program to distribute overdose reversal drugs, such as naloxone, to communities. Funding would flow to states, localities, and service providers through these grant mechanisms.
Who benefits
People with opioid addiction or other substance use disorders would gain access to expanded treatment and recovery services. Community organizations and healthcare providers offering addiction services would receive federal funding. Families and communities in areas with high rates of overdose deaths would benefit from wider availability of overdose reversal drugs. State and local governments would receive resources to address addiction-related public health burdens.
Who is hurt
Taxpayers would bear the cost of new federal spending. Existing addiction treatment and harm reduction programs not selected for grants could face competitive disadvantage. Some communities or advocacy groups may object to harm reduction approaches — such as needle exchanges or overdose reversal drug distribution — on the grounds that they may reduce incentives to seek treatment. Federal budget priorities in other areas could be displaced if funding is not offset.
Supporters argue
Supporters argue that the opioid epidemic has caused tens of thousands of deaths annually and constitutes a public health emergency requiring a large-scale federal response. They contend that treatment, recovery, and harm reduction services are proven to reduce overdose deaths and help people return to productive lives, but that these services are severely underfunded in many communities — particularly rural and low-income areas. Supporters also argue that distributing overdose reversal drugs like naloxone is a cost-effective, evidence-based intervention that saves lives immediately while connecting people to longer-term care. They maintain that the federal government has both the fiscal capacity and the constitutional authority under the Spending Clause to direct resources toward this national crisis.
Opponents argue
Opponents argue that creating new federal grant programs adds layers of bureaucracy and federal control over what are fundamentally state and local public health matters, potentially duplicating programs already administered by states. They contend that without clear spending offsets, the bill would add to the federal deficit and that the long-term cost of sustaining these programs is uncertain. Some opponents argue that harm reduction strategies — such as distributing overdose reversal drugs without requiring treatment enrollment — may reduce the urgency for individuals to seek recovery and could enable continued drug use. Others raise concerns that federal grant conditions could override state and local decisions about which treatment approaches best fit their communities.